ClinicalTrials.gg
CompletedNCT01064687AWARD-1Updated Jan 26, 2015Results posted

A Study in Participants With Type 2 Diabetes Mellitus

A Phase 3 interventional study of LY2189265 and Exenatide in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 89 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-26.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
978
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
4th of 54
978 · median 159
Started
2010
with 6 others
Phase 3
22 of 54
1 open now
Registered
5th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 7 that started in 2010, is one of 22 in phase 3, and was the 5th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.

Read the detailed description

During the study, if a participant developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, the participant received additional therapeutic intervention or initiation of an alternative antihyperglycemic medication following study drug discontinuation (rescue therapy). Participants who received rescue therapy were included in the analysis population, but only measurements obtained prior to the beginning of rescue therapy were included in specified analyses.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes (T2D) not well controlled on 1, 2, or 3 oral antidiabetic medications

    1. Glycosylated () greater than or equal to 7 and less than or equal to 11 if taking 1 oral antidiabetic medication
    2. HbA1c greater than or equal to 7 and less than or equal to 10 if on 2 or 3 oral antidiabetic medications
  • Able to tolerate minimum dose of 1500 milligrams (mg) metformin a day and 30 mg pioglitazone per day.
  • Willing to inject subcutaneous (SC) medication up to 2 times per day
  • Stable weight for 3 months prior to screening
  • (BMI) between 23 and 45 kilograms per meter squared (kg/m\^2)
  • Females of child bearing potential must test negative for pregnancy at screening by serum pregnancy test and be willing to use a reliable method of during the study and for 1 month following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes
  • equal to or less than 6.5 before randomization or at randomization
  • Chronic insulin use
  • Taking drugs to promote weight loss by prescription or over the counter
  • Taking systemic for greater than 14 days except for topical, eye, nasal, or inhaled
  • History of fluid retention or edema
  • History of Heart Failure New York Heart Classification II, III, or IV or acute myocardial infarction or stroke within 2 months of screening
  • Gastrointestinal (GI; stomach) problems such as diabetic gastroparesis or bariatric surgery (stomach stapling) or chronically taking drugs that directly affect GI motility
  • Hepatitis or liver disease or (ALT) greater than 2.5 times the
  • Acute or chronic pancreatitis of any form
  • Renal disease (kidney) with a serum creatinine of greater than or equal to 1.5 milligrams per deciliter (mg/dL) for males and greater than or equal to 1.4 mg/dL for females, or a creatine clearance of less than 60 milliliters per minute (mL/min)
  • History (includes family) of type 2A or 2B Multiple Endocrine Neoplasia (MEN 2A or 2B) or medullary c-cell hyperplasia or thyroid cancer
  • A serum calcitonin greater than or equal to 20 picograms per milliliter (pg/mL) at screening
  • Significant active disease such as Lupus or Rheumatoid Arthritis
  • History of or active except skin or in situ cervical or prostate cancer for within last 5 years
  • Sickle cell, hemolytic anemia, or other hematological condition that may interfere with HbA1c testing
  • Organ transplant except cornea
  • Have enrolled in another clinical trial within the last 30 days
  • Have previously signed an or participated in a LY2189265 (dulaglutide) study
  • Have taken a glucagon-like peptide 1 (GLP-1) receptor agonist within the 3 months prior to screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
978 participants (actual)

Study arms

  • Experimental
    1.5 mg LY2189265

    LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks

    Drug: LY2189265 · Drug: Metformin · Drug: Pioglitazone

  • Experimental
    0.75 mg LY2189265

    LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks

    Drug: LY2189265 · Drug: Metformin · Drug: Pioglitazone

  • Active comparator
    Exenatide

    Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks

    Drug: Exenatide · Drug: Metformin · Drug: Pioglitazone

  • Placebo comparator
    Placebo

    Placebo: subcutaneous (SC), once weekly for 26 weeks LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52). Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks

    Drug: LY2189265 · Drug: Placebo · Drug: Metformin · Drug: Pioglitazone

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, 26 weeks

Secondary outcomes

  1. Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, 52 weeks

  2. Change From Baseline to 26 Weeks for Body Weight

    Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  3. Change From Baseline to 52 Weeks for Body Weight

    Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  4. Change From Baseline to 26 Weeks on Body Mass Index (BMI)

    Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  5. Change From Baseline to 52 Weeks on Body Mass Index (BMI)

    Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  6. Change From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles

    The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  7. Change From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles

    The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  8. Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 26 Weeks

    The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.

    Time frame: Baseline, 26 weeks

  9. Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 52 Weeks

    The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.

    Time frame: Baseline, 52 weeks

  10. Change From Baseline to 26 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)

    The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  11. Change From Baseline to 52 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)

    The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  12. Change From Baseline to 26 Weeks in the EuroQol 5

    The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.

    Time frame: Baseline, 26 weeks

  13. Change From Baseline to 52 Weeks in the EuroQol 5

    The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.

    Time frame: Baseline, 52 weeks

  14. Change From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version

    The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). The DTSQ change version (DTSQc) was not collected at 26 weeks. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.

    Time frame: Baseline, 26 weeks

  15. Change From Baseline to 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) and Change (DTSQc) Versions

    The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) versions are used to assess participant treatment satisfaction at each study visit and relative change in satisfaction from baseline, respectively. Both questionnaires consist of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The change version has the same 8 items as the status version with a small alteration of the wording of Item 7. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied) for the DTSQs and from -18 (much less satisfied) to +18 (much more satisfied) for the DTSQc. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.

    Time frame: Baseline, 52 weeks

  16. Change From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living

    The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  17. Change From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living

    The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  18. Change From Baseline to 26 Weeks on the Impact of Weight on Self-Perception

    The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  19. Change From Baseline to 52 Weeks on the Impact of Weight on Self-Perception

    The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  20. Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks

    Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event since the previous inquiry. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  21. Change From Baseline to 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  22. Change From Baseline to 52 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  23. Change in Baseline to 26 Weeks on Pulse Rate

    Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  24. Change in Baseline to 52 Weeks on Pulse Rate

    Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  25. Change From Baseline to 26 Weeks on Blood Pressure

    Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks

  26. Change From Baseline to 52 Weeks on Blood Pressure

    Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52 weeks

  27. Number of Participants With Adjudicated Pancreatitis at 26 Weeks

    The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks

  28. Number of Participants With Adjudicated Pancreatitis at 52 Weeks

    The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only participants with confirmed pancreatitis during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  29. Change From Baseline to 26 Weeks on Pancreatic Enzymes

    Amylase (total and pancreas-derived) and lipase concentrations were measured.

    Time frame: Baseline, 26 weeks

  30. Change From Baseline to 52 Weeks on Pancreatic Enzymes

    Amylase (total and pancreas-derived) and lipase concentrations were measured.

    Time frame: Baseline, 52 weeks

  31. Change From Baseline to 26 Weeks on Serum Calcitonin

    Time frame: Baseline, 26 weeks

  32. Change From Baseline to 52 Weeks on Serum Calcitonin

    Time frame: Baseline, 52 weeks

  33. Number of Self-reported Hypoglycemic Events at 26 Weeks

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks

  34. Number of Self-reported Hypoglycemic Events at 52 Weeks

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  35. Rate of Self-reported Hypoglycemic Events at 26 Weeks

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks

  36. Rate of Self-reported Hypoglycemic Events at 52 Weeks

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  37. Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks

    Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia ("rescue therapy") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.

    Time frame: Baseline through 26 weeks

  38. Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks

    Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia ("rescue therapy") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.

    Time frame: Baseline through 52 weeks

  39. Number of Participants With LY2189265 Antibodies at 26 Weeks

    LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.

    Time frame: Baseline through 26 weeks

  40. Number of Participants With LY2189265 Antibodies at 52 Weeks and 4 Weeks After Last Dose of Study Drug

    LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.

    Time frame: 26 weeks through 52 weeks and 53 weeks through 4 weeks after last dose

  41. Number of Participants With Treatment Emergent Adverse Events at 26 Weeks

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks

  42. Number of Participants With Treatment Emergent Adverse Events at 52 Weeks

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only TEAEs that occurred during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  43. Change From Baseline to 26 Weeks in Hematological and Biochemical Lab Values

    Time frame: Baseline, 26 weeks

  44. Change From Baseline to 52 Weeks in Hematological and Biochemical Lab Values

    Time frame: Baseline, 52 weeks

  45. Change From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP)

    Time frame: Baseline, 26 weeks

  46. Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265

    Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

    Time frame: 4 weeks, 13 weeks, 26 weeks, and 52 weeks

07

Results

Posted Jan 26, 2015

Participant flow

Participant flow — Overall Study
Milestone1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Started279280278141
Received at least 1 dose of study drug279280276141
Completed 26 weeks260263252124
Completed245254237124
Not completed34264117
Withdrew: Adverse event94103
Withdrew: Death1100
Withdrew: Entry criteria not met3000
Withdrew: Lack of efficacy1023
Withdrew: Lost to follow-up710135
Withdrew: Physician decision2200
Withdrew: Protocol violation1101
Withdrew: Sponsor decision0030
Withdrew: Withdrawal by subject97125
Withdrew: Treatment noncompliance1110

Outcome measures

PrimaryChange From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)-1.51 ± 0.06-1.30 ± 0.06-0.99 ± 0.06-0.46 ± 0.08
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -1.05 · 95% CI -1.22 to -0.88
  • 1.5 mg LY2189265 vs Exenatide · ANCOVA · p = <0.0001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.52 · 95% CI -0.66 to -0.39
  • 0.75 mg LY2189265 vs Placebo · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.84 · 95% CI -1.01 to -0.67
  • 1.5 mg LY2189265 vs Exenatide · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.52 · 95% CI -0.66 to -0.39
  • 0.75 mg LY2189265 vs Exenatide · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.31 · 95% CI -0.44 to -0.18
  • 0.75 mg LY2189265 vs Exenatide · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.31 · 95% CI -0.44 to -0.18
SecondaryChange From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin1.5 mg LY21892650.75 mg LY2189265Exenatide
Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)-1.36 ± 0.08-1.07 ± 0.08-0.80 ± 0.08
Statistical analysis
  • 1.5 mg LY2189265 vs Exenatide · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.56 · 95% CI -0.73 to -0.39
  • 0.75 mg LY2189265 vs Exenatide · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.27 · 95% CI -0.44 to -0.11
  • 1.5 mg LY2189265 vs Exenatide · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.56 · 95% CI -0.73 to -0.39
  • 0.75 mg LY2189265 vs Exenatide · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.27 · 95% CI -0.44 to -0.11
SecondaryChange From Baseline to 26 Weeks for Body Weight

Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline to 26 Weeks for Body Weight
kilograms (kg)1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks for Body Weight-1.34 ± 0.250.18 ± 0.25-1.14 ± 0.261.37 ± 0.37
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -2.72 · 95% CI -3.58 to -1.85
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.571 · Ls mean difference: -0.20 · 95% CI -0.88 to 0.49
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.007 · Ls mean difference: -1.19 · 95% CI -2.06 to -0.33
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = <0.001 · Ls mean difference: 1.33 · 95% CI 0.64 to 2.01
  • Exenatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -2.52 · 95% CI -3.39 to -1.65
SecondaryChange From Baseline to 52 Weeks for Body Weight

Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline to 52 Weeks for Body Weight
kilograms (kg)1.5 mg LY21892650.75 mg LY2189265Exenatide
Change From Baseline to 52 Weeks for Body Weight-1.08 ± 0.340.49 ± 0.34-0.76 ± 0.35
Statistical analysis
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.507 · Ls mean difference: -0.32 · 95% CI -1.25 to 0.62
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.009 · Ls mean difference: 1.25 · 95% CI 0.32 to 2.19
SecondaryChange From Baseline to 26 Weeks on Body Mass Index (BMI)

Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · kilograms per meter squared (kg/m^2)
Change From Baseline to 26 Weeks on Body Mass Index (BMI)
kilograms per meter squared (kg/m^2)1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks on Body Mass Index (BMI)-0.48 ± 0.090.07 ± 0.09-0.41 ± 0.090.49 ± 0.13
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls means difference: -0.97 · 95% CI -1.27 to -0.67
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.568 · Ls mean difference: -0.07 · 95% CI -0.31 to 0.17
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.006 · Ls mean difference: -0.42 · 95% CI -0.72 to -0.12
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = <0.001 · Ls mean difference: 0.48 · 95% CI 0.24 to 0.71
  • Exenatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.90 · 95% CI -1.20 to -0.60
SecondaryChange From Baseline to 52 Weeks on Body Mass Index (BMI)

Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · kilograms per meter squared (kg/m^2)
Change From Baseline to 52 Weeks on Body Mass Index (BMI)
kilograms per meter squared (kg/m^2)1.5 mg LY21892650.75 mg LY2189265Exenatide
Change From Baseline to 52 Weeks on Body Mass Index (BMI)-0.37 ± 0.120.18 ± 0.12-0.28 ± 0.12
Statistical analysis
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.580 · Ls mean difference: -0.09 · 95% CI -0.42 to 0.23
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.005 · Ls mean difference: 0.46 · 95% CI 0.14 to 0.79
SecondaryChange From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles

The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles
milligrams per deciliter (mg/dL)1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles-46.82 ± 1.81-42.09 ± 1.87-37.48 ± 1.83-18.07 ± 2.68
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -28.76 · 95% CI -34.50 to -23.02
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -9.34 · 95% CI -13.62 to -5.06
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -24.02 · 95% CI -29.80 to -18.24
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.038 · Ls mean difference: -4.61 · 95% CI -8.95 to -0.27
  • Exenatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -19.41 · 95% CI -25.18 to -13.65
SecondaryChange From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles

The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles
milligrams per deciliter (mg/dL)1.5 mg LY21892650.75 mg LY2189265Exenatide
Change From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles-43.84 ± 2.07-40.62 ± 2.12-36.16 ± 2.11
Statistical analysis
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.004 · Ls mean difference: -7.68 · 95% CI -12.84 to -2.52
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.092 · Ls mean difference: -4.47 · 95% CI -9.66 to 0.73
SecondaryPercentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 26 Weeks

The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.

Time frame:
Baseline, 26 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 26 Weeks
percentage of participants1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
HbA1c Less Than 7%78.265.852.342.9
HbA1c Less Than or Equal to 6.5%62.753.238.024.4
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than 7.0%.) · Odds ratio (or): 13.1 · 95% CI 7.4 to 23.4
  • 1.5 mg LY2189265 vs Exenatide · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than 7.0%.) · Odds ratio (or): 6.2 · 95% CI 3.9 to 10.1
  • 0.75 mg LY2189265 vs Placebo · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than 7.0%.) · Odds ratio (or): 4.8 · 95% CI 2.8 to 8.0
  • 0.75 mg LY2189265 vs Exenatide · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than 7.0%.) · Odds ratio (or): 2.3 · 95% CI 1.5 to 3.5
  • Exenatide vs Placebo · Regression, Logistic · p = 0.004 (Treatment comparison for HbA1c less than 7.0%.) · Odds ratio (or): 2.1 · 95% CI 1.3 to 3.5
  • 1.5 mg LY2189265 vs Placebo · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5%.) · Odds ratio (or): 11.8 · 95% CI 6.7 to 20.8
  • 1.5 mg LY2189265 vs Exenatide · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5%.) · Odds ratio (or): 4.4 · 95% CI 2.9 to 6.8
  • 0.75 mg LY2189265 vs Placebo · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5%.) · Odds ratio (or): 6.3 · 95% CI 3.7 to 10.9
  • 0.75 mg LY2189265 vs Exenatide · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5%.) · Odds ratio (or): 2.4 · 95% CI 1.6 to 3.5
  • Exenatide vs Placebo · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5%.) · Odds ratio (or): 2.7 · 95% CI 1.6 to 4.6
SecondaryPercentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 52 Weeks

The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.

Time frame:
Baseline, 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 52 Weeks
percentage of participants1.5 mg LY21892650.75 mg LY2189265Exenatide
HbA1c Less Than 7.0%70.859.149.2
HbA1c Less Than or Equal to 6.5%57.248.334.6
Statistical analysis
  • 1.5 mg LY2189265 vs Exenatide · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than 7.0%.) · Odds ratio (or): 3.7 · 95% CI 2.4 to 5.6
  • 0.75 mg LY2189265 vs Exenatide · Regression, Logistic · p = 0.008 (Treatment comparison for HbA1c less than 7.0%.) · Odds ratio (or): 1.7 · 95% CI 1.1 to 2.5
  • 1.5 mg LY2189265 vs Exenatide · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5%.) · Odds ratio (or): 3.5 · 95% CI 2.3 to 5.1
  • 0.75 mg LY2189265 vs Exenatide · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5%.) · Odds ratio (or): 2.1 · 95% CI 1.4 to 3.1
SecondaryChange From Baseline to 26 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)

The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · percentage of HOMA2
Change From Baseline to 26 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)
percentage of HOMA21.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
HOMA2-%B36.14 ± 2.6023.61 ± 2.6715.02 ± 2.620.93 ± 3.66
HOMA2-%S-3.14 ± 2.911.16 ± 2.97-1.59 ± 2.922.56 ± 4.07
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-B) · Ls mean difference: 35.21 · 95% CI 27.26 to 43.16
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-B) · Ls mean difference: 21.12 · 95% CI 14.97 to 27.28
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-B) · Ls mean difference: 22.68 · 95% CI 14.63 to 30.72
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.007 (Treatment comparison of HOMA2-B) · Ls mean difference: 8.59 · 95% CI 2.31 to 14.87
  • Exenatide vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-B) · Ls mean difference: 14.09 · 95% CI 6.06 to 22.11
  • 1.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.207 (Treatment comparison of HOMA2-S) · Ls mean difference: -5.70 · 95% CI -14.56 to 3.17
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.659 (Treatment comparison of HOMA2-S) · Ls mean difference: -1.54 · 95% CI -8.41 to 5.32
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.759 (Treatment comparison of HOMA2-S) · Ls mean difference: -1.40 · 95% CI -10.37 to 7.56
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.441 (Treatment comparison of HOMA2-S) · Ls mean difference: 2.75 · 95% CI -4.25 to 9.76
  • Exenatide vs Placebo · Mixed Models Analysis · p = 0.362 (Treatment comparison of HOMA2-S) · Ls mean difference: -4.15 · 95% CI -13.10 to 4.79
SecondaryChange From Baseline to 52 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)

The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · percentage of HOMA2
Change From Baseline to 52 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)
percentage of HOMA21.5 mg LY21892650.75 mg LY2189265Exenatide
HOMA2-%B35.21 ± 2.6325.69 ± 2.7013.57 ± 2.75
HOMA2-%S-7.48 ± 2.93-5.49 ± 3.01-3.75 ± 3.07
Statistical analysis
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-B) · Ls mean difference: 21.64 · 95% CI 15.20 to 28.08
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-B) · Ls mean difference: 12.12 · 95% CI 5.56 to 18.68
  • 1.5 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.307 (Treatment comparison of HOMA2-S) · Ls mean difference: -3.73 · 95% CI -10.90 to 3.43
  • 0.75 mg LY2189265 vs Exenatide · Mixed Models Analysis · p = 0.638 (Treatment comparison of HOMA2-S) · Ls mean difference: -1.75 · 95% CI -9.05 to 5.55
SecondaryChange From Baseline to 26 Weeks in the EuroQol 5

The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 Weeks in the EuroQol 5
units on a scale1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
VAS Health State Score (n=270, 267, 264, 119)4.50 ± 0.852.41 ± 0.853.94 ± 0.850.71 ± 1.15
EQ-5D UK (n=270, 266, 264, 119)0.01 ± 0.010.01 ± 0.010.00 ± 0.01-0.00 ± 0.02
SecondaryChange From Baseline to 52 Weeks in the EuroQol 5

The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 52 Weeks in the EuroQol 5
units on a scale1.5 mg LY21892650.75 mg LY2189265Exenatide
VAS Health State Score (n=270, 267, 264)5.15 ± 0.893.52 ± 0.893.51 ± 0.89
EQ-5D UK (n=270, 266, 264)0.02 ± 0.010.01 ± 0.01-0.00 ± 0.01
SecondaryChange From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version

The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). The DTSQ change version (DTSQc) was not collected at 26 weeks. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version
units on a scale1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version2.40 ± 0.342.56 ± 0.330.85 ± 0.330.49 ± 0.45
SecondaryChange From Baseline to 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) and Change (DTSQc) Versions

The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) versions are used to assess participant treatment satisfaction at each study visit and relative change in satisfaction from baseline, respectively. Both questionnaires consist of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The change version has the same 8 items as the status version with a small alteration of the wording of Item 7. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied) for the DTSQs and from -18 (much less satisfied) to +18 (much more satisfied) for the DTSQc. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) and Change (DTSQc) Versions
units on a scale1.5 mg LY21892650.75 mg LY2189265Exenatide
DTSQs Treatment Satisfaction (n=270, 268, 266)2.05 ± 0.362.11 ± 0.360.69 ± 0.36
DTSQc Treatment Satisfaction (n=249, 237, 226)15.36 ± 0.4015.46 ± 0.4114.01 ± 0.41
SecondaryChange From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living

The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living
units on a scale1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living0.18 ± 0.270.12 ± 0.270.47 ± 0.270.03 ± 0.36
SecondaryChange From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living

The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living
units on a scale1.5 mg LY21892650.75 mg LY2189265Exenatide
Change From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living0.18 ± 0.29-0.18 ± 0.290.35 ± 0.29
SecondaryChange From Baseline to 26 Weeks on the Impact of Weight on Self-Perception

The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 Weeks on the Impact of Weight on Self-Perception
units on a scale1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks on the Impact of Weight on Self-Perception0.56 ± 0.150.47 ± 0.150.46 ± 0.150.45 ± 0.20
SecondaryChange From Baseline to 52 Weeks on the Impact of Weight on Self-Perception

The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 52 Weeks on the Impact of Weight on Self-Perception
units on a scale1.5 mg LY21892650.75 mg LY2189265Exenatide
Change From Baseline to 52 Weeks on the Impact of Weight on Self-Perception0.50 ± 0.150.47 ± 0.150.64 ± 0.15
SecondaryNumber of Participants With Adjudicated Cardiovascular Events at 52 Weeks

Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event since the previous inquiry. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks
participants1.5 mg LY21892650.75 mg LY2189265Exenatide
Any CV Event322
Any Fatal Event100
Any Non-fatal CV Event322
SecondaryChange From Baseline to 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline to 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
milliseconds (msec)1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
QTcF Interval (n=253, 260, 250, 120)-1.11 ± 1.000.91 ± 0.991.21 ± 1.001.32 ± 1.33
PR Interval (n=252, 259, 246, 116)2.35 ± 0.890.93 ± 0.881.01 ± 0.89-1.83 ± 1.20
SecondaryChange From Baseline to 52 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline to 52 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
milliseconds (msec)1.5 mg LY21892650.75 mg LY2189265Exenatide
QTcF Interval (n=239, 243, 226)1.28 ± 1.072.30 ± 1.072.52 ± 1.10
PR Interval (n=237, 243, 220)2.57 ± 0.960.69 ± 0.96-0.82 ± 0.99
SecondaryChange in Baseline to 26 Weeks on Pulse Rate

Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change in Baseline to 26 Weeks on Pulse Rate
beats per minute (bpm)1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change in Baseline to 26 Weeks on Pulse Rate2.80 ± 0.522.80 ± 0.511.18 ± 0.520.61 ± 0.70
SecondaryChange in Baseline to 52 Weeks on Pulse Rate

Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change in Baseline to 52 Weeks on Pulse Rate
beats per minute (bpm)1.5 mg LY21892650.75 mg LY2189265Exenatide
Change in Baseline to 52 Weeks on Pulse Rate1.68 ± 0.561.56 ± 0.551.15 ± 0.56
SecondaryChange From Baseline to 26 Weeks on Blood Pressure

Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 26 Weeks on Blood Pressure
millimeters of mercury (mmHg)1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Seated SBP (n=263, 266, 259, 127)0.11 ± 0.83-0.36 ± 0.820.06 ± 0.833.40 ± 1.13
Seated DBP (n=263, 266, 259, 127)0.76 ± 0.550.56 ± 0.54-0.11 ± 0.551.25 ± 0.75
SecondaryChange From Baseline to 52 Weeks on Blood Pressure

Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline to 52 Weeks on Blood Pressure
millimeters of mercury (mmHg)1.5 mg LY21892650.75 mg LY2189265Exenatide
Seated SBP (n=248, 256, 238)0.83 ± 0.871.62 ± 0.850.02 ± 0.88
Seated DBP (n=248, 256, 238)0.89 ± 0.570.76 ± 0.570.02 ± 0.58
SecondaryNumber of Participants With Adjudicated Pancreatitis at 26 Weeks

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis at 26 Weeks
participants1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Number of Participants With Adjudicated Pancreatitis at 26 Weeks0000
SecondaryNumber of Participants With Adjudicated Pancreatitis at 52 Weeks

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only participants with confirmed pancreatitis during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis at 52 Weeks
participants1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo/1.5 mg LY2189265Placebo/0.75 mg LY2189265
Number of Participants With Adjudicated Pancreatitis at 52 Weeks10000
SecondaryChange From Baseline to 26 Weeks on Pancreatic Enzymes

Amylase (total and pancreas-derived) and lipase concentrations were measured.

Time frame:
Baseline, 26 weeks
Reported as:
Median · units per liter
Change From Baseline to 26 Weeks on Pancreatic Enzymes
units per liter1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Amylase, Total (n=253, 253, 254, 127)12.50 ± 26.553.28 ± 24.245.56 ± 26.61-3.33 ± 27.51
Amylase, Pancreas-derived (n=237, 247, 246, 122)14.81 (0.00 to 35.00)10.34 (-5.88 to 26.67)5.56 (-7.14 to 21.05)-3.77 (-13.33 to 13.64)
Lipase (n=198, 203, 222, 114)10.34 (-7.50 to 29.41)0.00 (-15.91 to 23.08)3.94 (-10.26 to 23.08)-9.53 (-23.33 to 6.67)
SecondaryChange From Baseline to 52 Weeks on Pancreatic Enzymes

Amylase (total and pancreas-derived) and lipase concentrations were measured.

Time frame:
Baseline, 52 weeks
Reported as:
Median · units per liter
Change From Baseline to 52 Weeks on Pancreatic Enzymes
units per liter1.5 mg LY21892650.75 mg LY2189265Exenatide
Amylase, Total (n=255, 263, 261)9.21 (-4.95 to 23.19)2.78 (-11.67 to 17.50)2.38 (-11.86 to 15.22)
Amylase, Pancreas-derived (n=236, 253, 246)16.67 (0.00 to 35.60)7.69 (-8.70 to 28.00)7.85 (-8.82 to 26.67)
Lipase (n=201, 205, 221)5.45 (-7.69 to 26.92)0.00 (-18.18 to 15.63)3.57 (-13.95 to 22.58)
SecondaryChange From Baseline to 26 Weeks on Serum Calcitonin
Time frame:
Baseline, 26 weeks
Reported as:
Mean · picograms per milliliter (pg/mL)
Change From Baseline to 26 Weeks on Serum Calcitonin
picograms per milliliter (pg/mL)1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks on Serum Calcitonin0.20 ± 1.200.22 ± 1.910.05 ± 1.480.05 ± 0.89
SecondaryChange From Baseline to 52 Weeks on Serum Calcitonin
Time frame:
Baseline, 52 weeks
Reported as:
Mean · picograms per milliliter (pg/mL)
Change From Baseline to 52 Weeks on Serum Calcitonin
picograms per milliliter (pg/mL)1.5 mg LY21892650.75 mg LY2189265Exenatide
Change From Baseline to 52 Weeks on Serum Calcitonin0.21 ± 1.290.05 ± 1.790.10 ± 1.67
SecondaryNumber of Self-reported Hypoglycemic Events at 26 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks
Reported as:
Number · events
Number of Self-reported Hypoglycemic Events at 26 Weeks
events1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Severe HE0010
Documented Symptomatic HE31251464
Asymptomatic HE2695515
Nocturnal HE915316
Probable Symptomatic HE51633
SecondaryNumber of Self-reported Hypoglycemic Events at 52 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Number · events
Number of Self-reported Hypoglycemic Events at 52 Weeks
events1.5 mg LY21892650.75 mg LY2189265Exenatide
Severe HE002
Documented Symptomatic HE5339205
Asymptomatic HE4715798
Nocturnal HE202957
Probable Symptomatic HE8224
SecondaryRate of Self-reported Hypoglycemic Events at 26 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks
Reported as:
Mean · events per participant per year
Rate of Self-reported Hypoglycemic Events at 26 Weeks
events per participant per year1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Severe HE0.00 ± 0.000.00 ± 0.000.01 ± 0.120.00 ± 0.00
Documented symptomatic HE0.22 ± 1.940.18 ± 0.971.07 ± 4.900.06 ± 0.48
Asymptomatic HE0.19 ± 1.130.69 ± 4.740.38 ± 1.740.27 ± 2.44
Nocturnal HE0.06 ± 0.600.19 ± 1.740.23 ± 1.160.27 ± 2.51
Probable symptomatic HE0.04 ± 0.370.24 ± 2.440.02 ± 0.210.04 ± 0.51
SecondaryRate of Self-reported Hypoglycemic Events at 52 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Mean · events per participant per year
Rate of Self-reported Hypoglycemic Events at 52 Weeks
events per participant per year1.5 mg LY21892650.75 mg LY2189265Exenatide
Severe HE0.00 ± 0.000.00 ± 0.000.01 ± 0.09
Documented symptomatic HE0.19 ± 1.230.14 ± 0.780.76 ± 3.18
Asymptomatic HE0.17 ± 1.050.56 ± 3.570.37 ± 1.81
Nocturnal HE0.07 ± 0.630.19 ± 1.720.21 ± 1.06
Probable symptomatic HE0.03 ± 0.260.21 ± 2.380.02 ± 0.16
SecondaryNumber of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks

Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia ("rescue therapy") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.

Time frame:
Baseline through 26 weeks
Reported as:
Number · participants
Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks
participants1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks4141322
SecondaryNumber of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks

Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia ("rescue therapy") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks
participants1.5 mg LY21892650.75 mg LY2189265Exenatide
Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks102731
SecondaryNumber of Participants With LY2189265 Antibodies at 26 Weeks

LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.

Time frame:
Baseline through 26 weeks
Reported as:
Number · participants
Number of Participants With LY2189265 Antibodies at 26 Weeks
participants0.75 mg LY2189265 or 1.5 mg LY2189265ExenatidePlacebo
Number of Participants With LY2189265 Antibodies at 26 Weeks6122
SecondaryNumber of Participants With LY2189265 Antibodies at 52 Weeks and 4 Weeks After Last Dose of Study Drug

LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.

Time frame:
26 weeks through 52 weeks and 53 weeks through 4 weeks after last dose
Reported as:
Number · participants
Number of Participants With LY2189265 Antibodies at 52 Weeks and 4 Weeks After Last Dose of Study Drug
participants0.75 mg LY2189265 or 1.5 mg LY2189265ExenatidePlacebo/0.75 mg LY2189265 or 1.5 mg LY2189265
52 weeks322
4 weeks after last study dose101
SecondaryNumber of Participants With Treatment Emergent Adverse Events at 26 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events at 26 Weeks
participants1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Number of Participants With Treatment Emergent Adverse Events at 26 Weeks215199198104
SecondaryNumber of Participants With Treatment Emergent Adverse Events at 52 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only TEAEs that occurred during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events at 52 Weeks
participants1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo/1.5 mg LY2189265Placebo/0.75 mg LY2189265
Number of Participants With Treatment Emergent Adverse Events at 52 Weeks2262202214741
SecondaryChange From Baseline to 26 Weeks in Hematological and Biochemical Lab Values
Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean
Change From Baseline to 26 Weeks in Hematological and Biochemical Lab Values
Measure1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks in Hematological and Biochemical Lab ValuesNA ± NANA ± NANA ± NANA ± NA
SecondaryChange From Baseline to 52 Weeks in Hematological and Biochemical Lab Values
Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean
Change From Baseline to 52 Weeks in Hematological and Biochemical Lab Values
Measure1.5 mg LY21892650.75 mg LY2189265Exenatide
Change From Baseline to 52 Weeks in Hematological and Biochemical Lab ValuesNA ± NANA ± NANA ± NA
SecondaryChange From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP)
Time frame:
Baseline, 26 weeks
Reported as:
Median · picograms per milliliter (pg/mL)
Change From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP)
picograms per milliliter (pg/mL)1.5 mg LY21892650.75 mg LY2189265ExenatidePlacebo
Change From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP)-6.77 ± 91.13-2.96 ± 189.94-3.38 ± 208.92-0.85 ± 133.04
SecondaryPharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265

Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

Time frame:
4 weeks, 13 weeks, 26 weeks, and 52 weeks
Reported as:
Mean · nanogram hours per milliliter (ng*hr/mL)
Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265
nanogram hours per milliliter (ng*hr/mL)1.5 mg LY21892650.75 mg LY2189265
Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY218926512383 ± 54336627 ± 2487

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.75 mg LY2189265 (Baseline Through 26 Weeks)—15/280 (5.4%)194/280 (69.3%)
1.5 mg LY2189265 (Baseline Through 26 Weeks)—12/279 (4.3%)215/279 (77.1%)
Exenatide (Baseline Through 26 Weeks)—15/278 (5.4%)196/278 (70.5%)
Placebo (Baseline Through 26 Weeks)—12/141 (8.5%)103/141 (73%)
0.75 mg LY2189265 (Baseline Through 56 Weeks)—22/280 (7.9%)218/280 (77.9%)
1.5 mg LY2189265 (Baseline Through 56 Weeks)—18/279 (6.5%)228/279 (81.7%)
Exenatide (Baseline Through 56 Weeks)—27/278 (9.7%)223/278 (80.2%)
Placebo/0.75 mg LY2189265 (26 Weeks Through 56 Weeks)—6/62 (9.7%)47/62 (75.8%)
Placebo/1.5 mg LY2189265 (26 Weeks Through 56 Weeks)—9/62 (14.5%)55/62 (88.7%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
Event0.75 mg LY2189265 (Baseline Through 26 Weeks)1.5 mg LY2189265 (Baseline Through 26 Weeks)Exenatide (Baseline Through 26 Weeks)Placebo (Baseline Through 26 Weeks)0.75 mg LY2189265 (Baseline Through 56 Weeks)1.5 mg LY2189265 (Baseline Through 56 Weeks)Exenatide (Baseline Through 56 Weeks)Placebo/0.75 mg LY2189265 (26 Weeks Through 56 Weeks)Placebo/1.5 mg LY2189265 (26 Weeks Through 56 Weeks)
OsteomyelitisInfections and infestations0/2800/2790/2781/1411/2800/2790/2782/620/62
AnaemiaBlood and lymphatic system disorders0/2800/2790/2780/1410/2800/2790/2781/620/62
Acute myocardial infarctionCardiac disorders0/2800/2790/2780/1410/2801/2790/2781/620/62
Atrial fibrillationCardiac disorders0/2802/2790/2782/1410/2802/2790/2781/621/62
Coronary artery diseaseCardiac disorders1/2800/2791/2781/1411/2800/2791/2781/620/62
Myocardial ischaemiaCardiac disorders0/2800/2790/2781/1410/2800/2790/2780/621/62
Umbilical hernia, obstructiveGastrointestinal disorders0/2800/2790/2780/1410/2800/2790/2780/621/62
Chest painGeneral disorders0/2800/2790/2781/1410/2800/2790/2780/621/62
AbscessInfections and infestations0/2800/2790/2781/1410/2800/2790/2780/621/62
CellulitisInfections and infestations0/2801/2790/2781/1410/2802/2790/2781/620/62
Most frequent other events
Showing 10 of 22
Most frequent other events
Event0.75 mg LY2189265 (Baseline Through 26 Weeks)1.5 mg LY2189265 (Baseline Through 26 Weeks)Exenatide (Baseline Through 26 Weeks)Placebo (Baseline Through 26 Weeks)0.75 mg LY2189265 (Baseline Through 56 Weeks)1.5 mg LY2189265 (Baseline Through 56 Weeks)Exenatide (Baseline Through 56 Weeks)Placebo/0.75 mg LY2189265 (26 Weeks Through 56 Weeks)Placebo/1.5 mg LY2189265 (26 Weeks Through 56 Weeks)
NauseaGastrointestinal disorders45/28078/27971/2788/14147/28082/27977/2786/6215/62
VomitingGastrointestinal disorders17/28047/27930/2782/14117/28048/27934/2783/625/62
Oedema peripheralGeneral disorders13/2803/27911/2787/14115/2808/27917/2789/623/62
DiarrhoeaGastrointestinal disorders22/28031/27916/2788/14126/28037/27922/2785/628/62
NasopharyngitisInfections and infestations23/28018/27912/2788/14126/28028/27916/2785/622/62
DyspepsiaGastrointestinal disorders5/28022/27919/2784/1416/28023/27921/2780/626/62
HeadacheNervous system disorders9/28020/27924/2788/14114/28026/27925/2785/626/62
Upper respiratory tract infectionInfections and infestations14/28012/27912/2786/14125/28016/27920/2785/624/62
Decreased appetiteMetabolism and nutrition disorders14/28022/2798/2783/14115/28023/2799/2782/623/62
Urinary tract infectionInfections and infestations8/28011/2796/2784/14113/28016/27914/2782/625/62

Baseline characteristics

Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.

Age, Continuous
Age, Continuous(years)1.5 mg LY21892650.75 mg LY2189265ExenatidePlaceboTotal
Mean56.25 ± 9.7255.79 ± 9.4555.45 ± 10.1554.56 ± 10.0155.65 ± 9.81
Sex: Female, Male
Sex: Female, Male(Participants)1.5 mg LY21892650.75 mg LY2189265ExenatidePlaceboTotal
Female11611212058406
Male16316815683570
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1.5 mg LY21892650.75 mg LY2189265ExenatidePlaceboTotal
Hispanic or Latino931029145331
Not Hispanic or Latino18617818496644
Unknown or Not Reported00101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 mg LY21892650.75 mg LY2189265ExenatidePlaceboTotal
American Indian or Alaska Native40373820135
Asian684624
Native Hawaiian or Other Pacific Islander11103
Black or African American2424181076
White205207211103726
More than one race333211
Unknown or Not Reported00101
Region of Enrollment
Region of Enrollment(participants)1.5 mg LY21892650.75 mg LY2189265ExenatidePlaceboTotal
United States226226223113788
Mexico37363519127
Argentina161818961
Body Weight
Body Weight(kilograms)1.5 mg LY21892650.75 mg LY2189265ExenatidePlaceboTotal
Mean96.22 ± 19.6395.53 ± 20.5697.37 ± 18.8794.12 ± 19.2896.04 ± 19.64
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter squared (kg/m^2))1.5 mg LY21892650.75 mg LY2189265ExenatidePlaceboTotal
Mean33.09 ± 5.3333.00 ± 5.5033.54 ± 5.3632.90 ± 5.6633.16 ± 5.43
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)1.5 mg LY21892650.75 mg LY2189265ExenatidePlaceboTotal
Mean8.10 ± 1.348.05 ± 1.248.07 ± 1.348.06 ± 1.318.07 ± 1.31

2 further baseline measures are reported on the registry.

08

Study locations

89 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goodyear, Arizona 85395, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85028, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cathedral City, California 92234, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, California 94520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fresno, California 93720, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenbrae, California 94904, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lancaster, California 93534, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mission Hills, California 91345, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterey, California 93940, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    National City, California 91950, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oceanside, California 92056, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paramount, California 90723, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Roseville, California 95661, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Ramon, California 94583, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tustin, California 92780, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Britain, Connecticut 06050, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Lauderdale, Florida 33316, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hollywood, Florida 33021, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32806, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pembroke Pines, Florida 33027, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30308, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96813, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boise, Idaho 83702, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Idaho Falls, Idaho 83404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Meridian, Idaho 83646, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Crystal Lake, Illinois 60012, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peoria, Illinois 61615, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vincennes, Indiana 47591, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madisonville, Kentucky 42431, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Orleans, Louisiana 70112, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangor, Maine 04401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Biddeford, Maine 04005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Elkridge, Maryland 21075, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bloomfield Hills, Michigan 48302, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Flint, Michigan 48503, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashua, New Hampshire 03063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toms River, New Jersey 08753, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albany, New York 12206, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Flushing, New York 11365, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Syracuse, New York 13210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Asheville, North Carolina 28803, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cary, North Carolina 27518, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durham, North Carolina 27713, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morehead City, North Carolina 28557, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cincinnati, Ohio 45242, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cleveland, Ohio 44122, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbus, Ohio 43210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dayton, Ohio 45439, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Delaware, Ohio 43015, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Perrysburg, Ohio 43551, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bend, Oregon 97701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Corvallis, Oregon 97330, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Eugene, Oregon 97401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beaver, Pennsylvania 15009, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Danville, Pennsylvania 17822, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Levittown, Pennsylvania 19056, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19107, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wilkes Barre, Pennsylvania 18711, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina 29412, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenville, South Carolina 29605, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greer, South Carolina 29651, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Myrtle Beach, South Carolina 29572, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38119, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington, Texas 76014, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78731, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Corpus Christi, Texas 78404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75231, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    El Paso, Texas 79925, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78258, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Schertz, Texas 78154, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ogden, Utah 84403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. George, Utah 84790, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Jordan, Utah 84088, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tacoma, Washington 98405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, CBA 1419, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44600, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 6700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64461, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caguas, 00726, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hato Rey, 00917, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manati, 00674, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00716, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San German, 00683, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00907, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yabucoa, 00767, Puerto Rico
09

References and documents

Publications

  • Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016 Aug;18(8):820-8. doi: 10.1111/dom.12687. Epub 2016 Jun 7. PubMed 27161178 ↗
  • Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016 Apr;18(4):419-24. doi: 10.1111/dom.12624. Epub 2016 Feb 4. PubMed 26691396 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Nov 2011 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 3 years 2 months after primary completion. A results delay was requested in Feb 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2010
First posted
Feb 8, 2010
Start
Feb 2010
Primary completionActual
Nov 2011
CompletionActual
May 2012
Results delay requested
Feb 10, 2012
Results first posted
Jan 26, 2015
Last update
Jan 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01064687
Responsible party
Sponsor
First posted
Feb 8, 2010
Start date
Feb 2010
Primary completion
Nov 2011
Completion
May 2012
Results posted
Jan 26, 2015
Last update
Jan 26, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion